Dike Ojji, MBBS, PhD, FWACP, FACP, FESC
Dr Ojji had his basic medical education at University of Ibadan and his post graduate

training in Internal Medicine and Cardiology at University College Hospital Ibadan and
Royal Brisbane and Women Hospital, Brisbane, Australia. He also holds a PhD in
Cardiovascular Medicine from University of Cape Town South Africa. He is a fellow of
West African College of Physicians, American College of Physicians, Nigerian Cardiac
Society and European Society of Cardiology.
He is an Associate Professor of Preventive Cardiology at College of Health Sciences,
University of Abuja, and an Honorary Consultant Physician/Cardiologist at University of
Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria. He is also the Lead Investigator,
Cardiovascular Research Unit, University of Abuja and University of Abuja Teaching
Hospital, Gwagwalada, Abuja, and the Deputy Directors, Centre for Undergraduate Research and the Institute for Advanced Medical Research and Training both of University of Abuja. Dike also holds an Honorary Associate Professorship position at
Cape Heart Institute, Department of Medicine, University of Cape Town, Cape Town,
South Africa.
Dr. Ojji is a practicing cardiologist, researcher, and teacher, and he is interested in
global cardiovascular health epidemiology especially in the black population, clinical
trials in hypertension and heart failure, and policy research and training. His work spans
defining the spectrum of hypertensive heart disease and hypertensive heart failure in
the black population to hypertension pharmacotherapy in the same population, and
establishing a system for hypertension and cardiovascular care in the primary care level
in low- and middle- income countries.
He has been involved in a number of multinational observational and clinical trials
including RELY-Atrial Fibrillation registry, THESUS (The Sub-Saharan Africa Survey of
Heart Failure) study, IMPI (Prednisolone and Mycobacterium indicus pranii in
tuberculous pericarditis) trial, BA-HEF (Bi treatment with hydralazine/nitrates vs.
placebo in Africans admitted with acute HEart Failure) trial, REMEDY (Global
Rheumatic Heart Disease Registry), INTRE-CHF (International Congestive Heart
Failure) and ECHO Normal
He led the CREOLE (Comparison of Three Combination Therapies in Lowering Blood
Pressure in Black Africans) trial, which was a multi-centre, multinational, randomized
trial in 10 sites in 6 sub–Saharan African countries demonstrating the benefits of
calcium channel blocker-based dual therapy in the blacks residing in sub–Saharan
Africa. The result of this study was presented at the 2019 American College of
Cardiology Congress Late Breaking Clinical Session and published simultaneously in
the New England Journal of Medicine. He also led the 13-City and Nebivolol studies
which were multicenter studies conducted in different states in Nigeria.
He has over 91 manuscripts in peer reviewed journals including New England Journal of
Medicine, Nature Medicine, European Heart Journal, European Journal Heart Failure,

Journal Hypertension, American Heart Journal, American Journal of Hypertension,
Journal Human Hypertension, Journal American Medical Association, and the Lancet.
He is an Examiner at both the Membership and Fellowship Levels of West African
College of Physicians and examines both Masters’ and PhD thesis at Department of
Medicine, University of Cape Town, South Africa. Dr Ojji sits in the Scientific Committee
of World Heart Federation.
Dr. Ojji seeks to improve cardiovascular care in the black population residing in low-and
middle- income countries. He is married with two children.